PMID- 38191442
OWN - NLM
STAT- MEDLINE
DCOM- 20240110
LR  - 20240328
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 24
IP  - 1
DP  - 2024 Jan 8
TI  - Efficacy and safety of traditional Chinese medicine in the treatment of 
      menopause-like syndrome for breast cancer survivors: a systematic review and 
      meta-analysis.
PG  - 42
LID - 10.1186/s12885-023-11789-z [doi]
LID - 42
AB  - BACKGROUND: In recent years, breast cancer (BC) incidence and mortality have been 
      the highest in females. Menopause-like syndrome (MLS), arising from 
      hypoestrogenism caused by endocrine therapy, significantly affects the quality of 
      life for females. Traditional Chinese Medicine (TCM) has advantages in 
      ameliorating MLS, but the efficacy of TCM in patients with BC has not been 
      systematically evaluated. METHODS: A comprehensive search was performed on 
      PubMed, Web of Science, Embase, Ovid, Cochrane Library, China National Knowledge 
      Infrastructure, Wanfang database, Chinese Scientific Journals Database, and 
      Clinical Trial Registry from inception to September 4, 2023. The Cochrane Risk of 
      Bias assessment tool was used for the quality evaluation of the randomized 
      controlled trials (RCTs). Review Manager 5.4 software was used for statistical 
      analysis, and the Grading of Recommendations Assessment, Development, and 
      Evaluation was used for quality evaluation of the synthesized evidence. RESULTS: 
      This review included 42 studies involving 3112 female patients with BC. The 
      results showed that the TCM group was better at decreasing the Kupperman 
      Menopausal Index (KMI) scores (standardized MD, SMD = - 1.84, 95% confidence 
      interval, CI [- 2.21--1.46], Z = 9.63, P < 0.00001). Regarding the main symptoms 
      of MLS, the TCM groups could significantly decrease the scores of hot flashes and 
      night sweats (SMD = - 0.68, 95% CI [- 1.1--0.27], Z = 3.24, P = 0.001), 
      paraesthesia (SMD = - 0.48, 95% CI [- 0.74--0.21], Z = 3.53, P = 0.0004), 
      osteoarthralgia (SMD = - 0.41, 95% CI [- 0.6-0.21], Z = 4.09, P < 0.0001), 
      anxiety (MD = - 0.85, 95% CI [- 1.13, - 0.58], Z = 6.08, P < 0.00001) and 
      insomnia (MD = - 0.61, 95% CI [- 0.8, - 0.43], Z = 6.51, P < 0.00001). TCM can 
      effectively improve the symptoms of MLS in patients with BC. Moreover, TCM could 
      improve the objective response rate (ORR) by 50% (RR = 1.5, 95% CI [1.37-1.64], 
      Z = 9.01, P < 0.00001). Follicle-stimulating hormone (FSH) and oestradiol (E(2)) 
      had no significant difference compared with the control group (p = 0.81 and 
      p = 0.87), and luteinizing hormone (LH) in the TCM group decreased significantly 
      (MD = - 0.99, 95% CI [- 1.38, - 0.5], Z = 5.01, P < 0.00001). This means that the 
      use of TCM does not negatively affect endocrine therapy and may even have a 
      synergistic effect. The incidence of adverse events (AEs) was lower in the TCM 
      groups than in the control groups. CONCLUSIONS: The meta-analysis stated that TCM 
      could better improve the MLS of patients, alleviate related symptoms, and did not 
      increase adverse drug reactions in BC survivors. This review brings more 
      attention to MLS, and the present findings shed light on the potential 
      applications of TCM in the treatment of MLS in BC survivors.
CI  - (c) 2024. The Author(s).
FAU - Wang, Runxi
AU  - Wang R
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences, Beijing, China.
FAU - Wang, Yan
AU  - Wang Y
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences, Beijing, China.
FAU - Fang, Liyuan
AU  - Fang L
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences, Beijing, China.
FAU - Xie, Yi
AU  - Xie Y
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences, Beijing, China.
AD  - Beijing University of Chinese Medicine, Beijing, China.
FAU - Yang, Shuhan
AU  - Yang S
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences, Beijing, China.
AD  - Beijing University of Chinese Medicine, Beijing, China.
FAU - Liu, Suying
AU  - Liu S
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences, Beijing, China.
FAU - Fang, Yuhang
AU  - Fang Y
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences, Beijing, China.
AD  - Beijing University of Chinese Medicine, Beijing, China.
FAU - Zhang, Ying
AU  - Zhang Y
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences, Beijing, China. zylzy501@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20240108
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
SB  - IM
MH  - Female
MH  - Humans
MH  - *Breast Neoplasms/drug therapy
MH  - *Cancer Survivors
MH  - *Medicine, Chinese Traditional/adverse effects
MH  - *Menopause/drug effects
MH  - Syndrome
PMC - PMC10773128
OTO - NOTNLM
OT  - Breast cancer
OT  - Endocrine therapy
OT  - Menopause-like syndrome
OT  - Systematic review
OT  - meta-analysis
COIS- The authors declare no competing interests.
EDAT- 2024/01/09 00:42
MHDA- 2024/01/10 06:42
PMCR- 2024/01/08
CRDT- 2024/01/08 23:40
PHST- 2023/09/13 00:00 [received]
PHST- 2023/12/22 00:00 [accepted]
PHST- 2024/01/10 06:42 [medline]
PHST- 2024/01/09 00:42 [pubmed]
PHST- 2024/01/08 23:40 [entrez]
PHST- 2024/01/08 00:00 [pmc-release]
AID - 10.1186/s12885-023-11789-z [pii]
AID - 11789 [pii]
AID - 10.1186/s12885-023-11789-z [doi]
PST - epublish
SO  - BMC Cancer. 2024 Jan 8;24(1):42. doi: 10.1186/s12885-023-11789-z.